Journals / Klinik Psikofarmakoloji Bülteni / 2010 / Cilt: 20 - Sayı: 1

Aripiprazole use in children and adolescents: a case series

Çocuk ve gençlerde aripiprazol kullanımı: Olgu serisi

Pages
84–93
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, prospective clinical trials with a randomized placebo controlled design are needed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In children and adolescents, atypical antipsychotics have been largely used to treat aggression, mood instability, and psychosis.
📊
Key Findings & Data:A series of 7 children and adolescents (ages 11–17 years, 5 males) were treated with aripiprazole for different psychiatric disorders.
💡
Conclusion & Impact:However, prospective clinical trials with a randomized placebo controlled design are needed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In children and adolescents, atypical antipsychotics have been largely used to treat aggression, mood instability, and psychosis. There is a growing interest in the use of aripiprazole in children and adolescents with schizophrenia, pervasive developmental disorders, and bipolar disorders. A series of 7 children and adolescents (ages 11–17 years, 5 males) were treated with aripiprazole for different psychiatric disorders. All patients had been treated previously with several psychotropic drugs. Aripiprazole was initiated at a starting dose of 2.5 or 5 mg daily and optimal dosages ranged from 5 to 10 mg daily. Six of the 7 patients appeared to benefit from aripiprazole. Neither extrapyramidal side effects nor agitation was observed in any case. Aripiprazole was well tolerated and effective in our cases and appears to be a safe and efficacious alternative in the child and adolescents. However, prospective clinical trials with a randomized placebo controlled design are needed.

Özet

Çocuk ve gençlerde atipik antipsikotikler saldırganlık, duygudurumda değişkenlik ve psikoz tedavisinde yaygın olarak kullanılmaktadır. Aripiprazolün şizofreni, yaygın gelişimsel bozukluk ve bipolar bozukluğu olan çocuk ve gençlerde kullanımına ilişkin ilgi artmaktadır. Farklı psikiyatrik bozukluğu olan 11-17 yaş arasındaki beşi erkek 7 çocuk ve genç aripiprazol ile tedavi edilmiştir. Hastaların tümüne daha önce farklı psikiyatrik ilaçlar ile tedavi uygulanmıştır. Aripiprazol günlük 2.5 ya da 5 mg dozda başlanmıştır ve optimal doz günde 5 ile 10 mg arasında değişmektedir. Yedi hastanın altısının aripiprazol tedavisinden yararlandığı görülmüştür. Ekstrapiramidal yan etki ya da ajitasyon gözlenmemiştir. Aripiprazol hastalarımızda iyi tolere edilmiştir ve çocuk ve gençlerde güvenilir ve etkin bir seçenek gibi görünmektedir. Ancak randomize kontrollü ileriye dönük klinik çalışmaların yapılması gerekmektedir

🔖

Cite This Article

BİLDİK, T., ÖZBARAN, N. B., KÜÇÜKKÖSE, M., ARDIÇ, Ü. A. (2022). Aripiprazole use in children and adolescents: a case series. Klinik Psikofarmakoloji Bülteni, Cilt: 20 - Sayı: 1, 84–93. https://ajindex.com/articles/574240

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 2004; 26: 649-666
  2. Storch EA, Lehmkuhl H, Geffken G, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 2008; 25: 172-174
  3. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165: 1432-1441
  4. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, et al. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr 2007; 12: 683-689
  5. Tramontina S, Zeni CP, Ketzer CR, Pheula GF, Narvaez J, Rohde LA. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry 2009; 70: 756-764
  6. Stigler KA, Diener JT, Kohn AE, Li L, Erickson CA, Posey DJ, McDougle CJ. Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study. J Child Adolesc Psychopharmacol 2009; 19: 265-274
  7. Masi G, Cosenza A, Millepiedi S, Muratori F, Pari C, Salvadori F. Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study. CNS Drugs 2009; 23: 511-521
  8. Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol 2008; 18: 197-205
  9. Curtis AR, Richards RW. The Treatment of Psychogenic Excoriation and Obsessive Compulsive Disorder Using Aripiprazole and Fluoxetine. Ann Clin Psychiatry 2007; 19: 199-200
  10. Rugino TA, Janvier YM. Aripiprazole in children and adolescents: clinical experience. J Child Neurol 2005; 20: 603-610
  11. Akdemir A, Örsel SD, Dağ İ ve ark. Hamilton Depresyon Derecelendirme Ölçeğinin geçerliliği-güvenilirliği ve klinikte kullanımı. 3P (Psikiyatri Psikoloji ve Psikofarmakoloji) Dergisi 1996; 4: 251-259
  12. Karadağ F, Oral ET, Yalçın FA ve ark. Young Mani Derecelendirme Ölçeğinin Türkiye’de geçerlik ve güvenirliği. Türk Psikiyatri Dergisi 2002; 13: 107-114
  13. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Depart